These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 31242884)

  • 1. Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression.
    Kanba S; Murasaki M; Koyama T; Takeuchi M; Shimizu Y; Arita E; Kuroishi K; Takeuchi M; Kamei S
    BMC Psychiatry; 2019 Jun; 19(1):198. PubMed ID: 31242884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression.
    Murasaki M; Koyama T; Kanba S; Takeuchi M; Shimizu Y; Arita E; Kuroishi K; Takeuchi M; Kamei S
    Psychopharmacology (Berl); 2018 Oct; 235(10):2859-2869. PubMed ID: 30069587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
    Cutler AJ; Datto C; Nordenhem A; Minkwitz M; Acevedo L; Darko D
    Clin Ther; 2011 Nov; 33(11):1643-58. PubMed ID: 22054797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of quetiapine extended release monotherapy in bipolar depression: a multi-center, randomized, double-blind, placebo-controlled trial.
    Li H; Gu N; Zhang H; Wang G; Tan Q; Yang F; Ning Y; Zhang H; Lu Z; Xu X; Shi J; Gao C; Li L; Zhang K; Tian H; Wang X; Li K; Li H; Xu Y; Xie S; Yu X
    Psychopharmacology (Berl); 2016 Apr; 233(7):1289-97. PubMed ID: 26911380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use.
    Gao K; Ganocy SJ; Conroy C; Brownrigg B; Serrano MB; Calabrese JR
    Psychopharmacology (Berl); 2017 Aug; 234(15):2233-2244. PubMed ID: 28536866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial.
    Findling RL; Pathak S; Earley WR; Liu S; DelBello MP
    J Child Adolesc Psychopharmacol; 2014 Aug; 24(6):325-35. PubMed ID: 24956042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder.
    Bauer M; Thase ME; Liu S; Earley W; Eriksson H
    J Psychopharmacol; 2015 May; 29(5):565-74. PubMed ID: 25257148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
    Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder.
    Katila H; Mezhebovsky I; Mulroy A; Berggren L; Eriksson H; Earley W; Datto C
    Am J Geriatr Psychiatry; 2013 Aug; 21(8):769-84. PubMed ID: 23567397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quetiapine: a review of its use in the management of bipolar depression.
    Sanford M; Keating GM
    CNS Drugs; 2012 May; 26(5):435-60. PubMed ID: 22519923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Results from a pilot, randomized controlled trial.
    Garriga M; Solé E; González-Pinto A; Selva-Vera G; Arranz B; Amann BL; Saiz-Ruiz J; Pérez-Blanco J; Vieta E
    Eur Neuropsychopharmacol; 2017 Oct; 27(10):959-969. PubMed ID: 28882405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan.
    Kishi T; Yoshimura R; Sakuma K; Okuya M; Iwata N
    Neuropsychopharmacol Rep; 2020 Dec; 40(4):417-422. PubMed ID: 32902200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.
    Bauer M; Dell'osso L; Kasper S; Pitchot W; Dencker Vansvik E; Köhler J; Jørgensen L; Montgomery SA
    J Affect Disord; 2013 Oct; 151(1):209-19. PubMed ID: 23810357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder.
    Mezhebovsky I; Mägi K; She F; Datto C; Eriksson H
    Int J Geriatr Psychiatry; 2013 Jun; 28(6):615-25. PubMed ID: 23070803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics Analysis of Quetiapine Extended-release Formulation in Japanese Patients with Bipolar Depression.
    Fukushi R; Nomura Y; Katashima M; Komatsu K; Sato Y; Takada A
    Clin Ther; 2020 Jun; 42(6):1067-1076.e2. PubMed ID: 32518042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression.
    Suppes T; Datto C; Minkwitz M; Nordenhem A; Walker C; Darko D
    J Affect Disord; 2010 Feb; 121(1-2):106-15. PubMed ID: 19903574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.
    Liebowitz M; Lam RW; Lepola U; Datto C; Sweitzer D; Eriksson H
    Depress Anxiety; 2010 Oct; 27(10):964-76. PubMed ID: 20734365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo-controlled trial.
    Gao K; Wu R; Kemp DE; Chen J; Karberg E; Conroy C; Chan P; Ren M; Serrano MB; Ganocy SJ; Calabrese JR
    J Clin Psychiatry; 2014 Oct; 75(10):1062-8. PubMed ID: 25007003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study.
    Hirschfeld RM; Weisler RH; Raines SR; Macfadden W;
    J Clin Psychiatry; 2006 Mar; 67(3):355-62. PubMed ID: 16649820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.